世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

免疫チェックポイント阻害剤の市場:種類(CTLA-4阻害剤、PD-1阻害剤、PD-L1阻害剤)、流通チャネル(病院薬局、小売薬局、オンライン薬局)、用途(肺がん、膀胱がん、メラノーマ、大腸がん、ホジキンリンパ腫、その他)、地域 2023-2028


Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin Lymphoma, and Others), and Region 2023-2028

市場の概要 免疫チェックポイント阻害剤の世界市場規模は、2022年に366億米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に17.19%の成長率(CAGR)を示し、2028年までに973億米ドルに達すると... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
IMARC Services Private Limited.
アイマークサービス
2023年3月18日 US$2,499
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
143 英語

 

サマリー

市場の概要

免疫チェックポイント阻害剤の世界市場規模は、2022年に366億米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に17.19%の成長率(CAGR)を示し、2028年までに973億米ドルに達すると予測しています。様々な癌の有病率の上昇、呼吸器疾患の増加、個別化された医薬品への嗜好の高まりなどが、市場を牽引する主要な要因の一つです。

免疫チェックポイント阻害剤は、T細胞などの免疫系細胞やがん細胞が作る特定のタンパク質を阻害することにより、がんの治療に利用される薬剤です。単独で、あるいは化学療法や放射線療法など他のがん治療と組み合わせて使用することで、治療効果を高めることができます。また、病気の症状を軽減し、生存期間を延ばすことで、がん患者さんのQOL(生活の質)を高めることに貢献します。免疫チェックポイント阻害剤は、免疫系の特定の経路を標的とするため、がん治療においてより的を絞ったアプローチが可能となります。また、これらの阻害剤は、従来の化学療法と比較して、副作用が少なく、患者さんへの耐性が高いという毒性プロファイルを持っています。現在、がん細胞内の特定の遺伝子変異を同定することができる次世代シーケンサー技術の利用が増加しており、世界中で免疫チェックポイント阻害剤の需要が高まっています。

免疫チェックポイント阻害剤の市場動向:

メラノーマ、肝臓、腎臓、胃などの様々な癌の急増は、免疫チェックポイント阻害剤の世界的な需要を促進する主要な要因の一つとなっています。さらに、このような深刻ながんを発症しやすい高齢者人口の増加や、肥満の有病率の上昇が、市場の成長に好影響を与えています。さらに、アルコール飲料やタバコの消費量の増加により、呼吸器疾患の発生が増加しています。さらに、不健康な食習慣や座りっぱなしの生活習慣により、体重に関連した健康上の懸念が増加していることも、市場にプラスの影響を与えています。これとは別に、さまざまな遺伝性疾患や生活習慣病の急増、がんの早期診断と治療の利点に関する個人や医療従事者の意識の高まりが、市場の成長を後押ししています。さらに、製薬会社による臨床試験数の拡大、個別化医療や新世代の医薬品・製剤への嗜好の高まりも、市場の成長を後押ししています。このほか、製品ポートフォリオを拡大し競争力を高めるために、戦略的提携や新製品開発に注力する大手企業の動きが活発化していることも、市場に明るい展望を生み出しています。さらに、医療インフラや診断技術の大幅な向上が、市場の成長を強化すると予想されています。

主要な市場セグメント:

IMARC Groupは、世界の免疫チェックポイント阻害剤市場の各セグメントにおける主要動向の分析、および2023年から2028年までの世界、地域、国レベルでの予測を提供しています。当レポートでは、市場をタイプ、流通チャネル、アプリケーションに基づき分類しています。

タイプのインサイトです:

CTLA-4 インヒビター
PD-1インヒビター
PD-L1インヒビター


本レポートでは、免疫チェックポイント阻害剤市場をタイプ別に詳細に分解・分析しています。これには、CTLA-4阻害剤、PD-1阻害剤、PD-L1阻害剤が含まれます。それによると、PD-1阻害剤は最大のセグメントを占めています。

ディストリビューション・チャネル・インサイト

病院内薬局
小売薬局
オンラインファーマシーズ


また、免疫チェックポイント阻害剤市場について、流通チャネルに基づく詳細な分類と分析も行っています。これには、病院薬局、小売薬局、オンライン薬局が含まれます。報告書によると、病院薬局が最大の市場シェアを占めています。

アプリケーションインサイト

肺がん
膀胱がん(Bladder Cancer
メラノーマ
大腸がん(Colorectal Cancer
ホジキンリンパ腫
その他


本レポートでは、免疫チェックポイント阻害剤市場を用途別に詳細に分解・分析しています。これには、肺がん、膀胱がん、メラノーマ、結腸直腸がん、ホジキンリンパ腫、その他が含まれます。それによると、肺がんが最大のセグメントを占めています。

地域別インサイト

北アメリカ

ユーエスエー
カナダ


アジア太平洋

中国
日本
インド
南朝鮮
オーストラリア
インドネシア
その他


ヨーロッパ

ドイツ
フランス
イギリス
イタリア
スペイン
ロシア
その他


ラテンアメリカ

ブラジル
メキシコ
その他


中近東・アフリカ


また、北米(米国、カナダ)、アジア太平洋(中国、日本、インド、韓国、オーストラリア、インドネシア、その他)、欧州(ドイツ、フランス、英国、イタリア、スペイン、ロシア、その他)、中南米(ブラジル、メキシコ、その他)、中東・アフリカの主要地域市場すべてについて包括的に分析しています。それによると、免疫チェックポイント阻害剤の市場は、北米が最大でした。北米の免疫チェックポイント阻害剤市場を牽引する要因としては、高齢化人口の増加、確立された医療インフラの存在、研究開発(R&D)活動の活発化などが挙げられます。

競合の状況:

また、世界の免疫チェックポイント阻害剤市場における競争環境についても包括的な分析を行っています。市場構造、主要プレイヤーによる市場シェア、プレイヤーのポジショニング、トップの勝利戦略、競合ダッシュボード、企業評価象限などの競争分析が、本レポートでカバーされています。また、すべての主要企業の詳細なプロフィールが提供されています。対象となる企業には、AstraZeneca plc、Bristol-Myers Squibb Company、GSK plc、Merck & Co.Inc.、小野薬品工業Inc.Ltd.、Pfizer Inc.、Regeneron Pharmaceuticals Inc.、Seagen Inc.などです。なお、これは企業の一部のリストであり、完全なリストは報告書に記載されています。

本レポートで回答した主な質問

免疫チェックポイント阻害剤の世界市場はこれまでどのように推移し、今後数年間はどのように推移するのか?
世界の免疫チェックポイント阻害剤市場における推進要因、阻害要因、機会は何か?
各駆動因子、阻害因子、機会が世界の免疫チェックポイント阻害剤市場に与える影響は?
主要な地域市場とは?
最も魅力的な免疫チェックポイント阻害剤市場を代表する国はどこか?
タイプ別の市場の内訳は?
免疫チェックポイント阻害剤市場において最も魅力的なタイプは何か?
販売チャネルに基づく市場の内訳は?
免疫チェックポイント阻害剤市場において最も魅力的な流通チャネルはどこか?
アプリケーションに基づく市場の内訳は?
免疫チェックポイント阻害剤市場において最も魅力的なアプリケーションは何か?
世界の免疫チェックポイント阻害剤市場の競争構造は?
免疫チェックポイント阻害剤の世界市場における主要なプレイヤー/企業はどこか?



ページTOPに戻る


目次

1    Preface
2    Scope and Methodology
    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction
    4.1    Overview
    4.2    Key Industry Trends
5    Global Immune Checkpoint Inhibitors Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Type
    6.1    CTLA-4 Inhibitor
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    PD-1 Inhibitor
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    PD-L1 Inhibitor
        6.3.1 Market Trends
        6.3.2 Market Forecast
7    Market Breakup by Distribution Channel
    7.1    Hospital Pharmacies
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Retail Pharmacies
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Online Pharmacies
        7.3.1 Market Trends
        7.3.2 Market Forecast
8    Market Breakup by Application
    8.1    Lung Cancer
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Bladder Cancer
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Melanoma
        8.3.1 Market Trends
        8.3.2 Market Forecast
    8.4    Colorectal Cancer
        8.4.1 Market Trends
        8.4.2 Market Forecast
    8.5    Hodgkin Lymphoma
        8.5.1 Market Trends
        8.5.2 Market Forecast
    8.6    Others
        8.6.1 Market Trends
        8.6.2 Market Forecast
9    Market Breakup by Region
    9.1    North America
        9.1.1 United States
           9.1.1.1 Market Trends
           9.1.1.2 Market Forecast
        9.1.2 Canada
           9.1.2.1 Market Trends
           9.1.2.2 Market Forecast
    9.2    Asia-Pacific
        9.2.1 China
           9.2.1.1 Market Trends
           9.2.1.2 Market Forecast
        9.2.2 Japan
           9.2.2.1 Market Trends
           9.2.2.2 Market Forecast
        9.2.3 India
           9.2.3.1 Market Trends
           9.2.3.2 Market Forecast
        9.2.4 South Korea
           9.2.4.1 Market Trends
           9.2.4.2 Market Forecast
        9.2.5 Australia
           9.2.5.1 Market Trends
           9.2.5.2 Market Forecast
        9.2.6 Indonesia
           9.2.6.1 Market Trends
           9.2.6.2 Market Forecast
        9.2.7 Others
           9.2.7.1 Market Trends
           9.2.7.2 Market Forecast
    9.3    Europe
        9.3.1 Germany
           9.3.1.1 Market Trends
           9.3.1.2 Market Forecast
        9.3.2 France
           9.3.2.1 Market Trends
           9.3.2.2 Market Forecast
        9.3.3 United Kingdom
           9.3.3.1 Market Trends
           9.3.3.2 Market Forecast
        9.3.4 Italy
           9.3.4.1 Market Trends
           9.3.4.2 Market Forecast
        9.3.5 Spain
           9.3.5.1 Market Trends
           9.3.5.2 Market Forecast
        9.3.6 Russia
           9.3.6.1 Market Trends
           9.3.6.2 Market Forecast
        9.3.7 Others
           9.3.7.1 Market Trends
           9.3.7.2 Market Forecast
    9.4    Latin America
        9.4.1 Brazil
           9.4.1.1 Market Trends
           9.4.1.2 Market Forecast
        9.4.2 Mexico
           9.4.2.1 Market Trends
           9.4.2.2 Market Forecast
        9.4.3 Others
           9.4.3.1 Market Trends
           9.4.3.2 Market Forecast
    9.5    Middle East and Africa
        9.5.1 Market Trends
        9.5.2 Market Breakup by Country
        9.5.3 Market Forecast
10    Drivers, Restraints, and Opportunities
    10.1    Overview
    10.2    Drivers
    10.3    Restraints
    10.4    Opportunities
11    Value Chain Analysis
12    Porters Five Forces Analysis
    12.1    Overview
    12.2    Bargaining Power of Buyers
    12.3    Bargaining Power of Suppliers
    12.4    Degree of Competition
    12.5    Threat of New Entrants
    12.6    Threat of Substitutes
13    Price Analysis
14    Competitive Landscape
    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    AstraZeneca plc
           14.3.1.1 Company Overview
           14.3.1.2 Product Portfolio
           14.3.1.3 Financials
           14.3.1.4 SWOT Analysis
        14.3.2    Bristol-Myers Squibb Company
           14.3.2.1 Company Overview
           14.3.2.2 Product Portfolio
           14.3.2.3 Financials
           14.3.2.4 SWOT Analysis
        14.3.3    GSK plc
           14.3.3.1 Company Overview
           14.3.3.2 Product Portfolio
           14.3.3.3 Financials
           14.3.3.4 SWOT Analysis
        14.3.4    Merck & Co. Inc.
           14.3.4.1 Company Overview
           14.3.4.2 Product Portfolio
           14.3.4.3 Financials
           14.3.4.4 SWOT Analysis
        14.3.5    Ono Pharmaceutical Co. Ltd.
           14.3.5.1 Company Overview
           14.3.5.2 Product Portfolio
           14.3.5.3 Financials
           14.3.5.4 SWOT Analysis
        14.3.6    Pfizer Inc.
           14.3.6.1 Company Overview
           14.3.6.2 Product Portfolio
           14.3.6.3 Financials
           14.3.6.4 SWOT Analysis
        14.3.7    Regeneron Pharmaceuticals Inc.
           14.3.7.1 Company Overview
           14.3.7.2 Product Portfolio
           14.3.7.3 Financials
           14.3.7.4 SWOT Analysis
        14.3.8    Seagen Inc. 
           14.3.8.1 Company Overview
           14.3.8.2 Product Portfolio
           14.3.8.3 Financials
           14.3.8.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges
Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2022
Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2022
Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2022
Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2022
Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2022
Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities
Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis
Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2022 & 2028
Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million US$), 2023-2028
Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million US$), 2023-2028
Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure
Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players

 

ページTOPに戻る


 

Summary

Market Overview:

The global immune checkpoint inhibitors market size reached US$ 36.6 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 97.3 Billion by 2028, exhibiting a growth rate (CAGR) of 17.19% during 2023-2028. The rising prevalence of various cancers, increasing incidences of respiratory disorders, and the growing preference for personalized medicines represent some of the key factors driving the market.

Immune checkpoint inhibitors are drugs utilized for treating cancer by inhibiting specific proteins made by immune system cells, such as T cells and cancer cells. They are either used alone or in combination with other cancer treatments, such as chemotherapy and radiation therapy to enhance treatment outcomes. They aid in enhancing the quality of life for cancer patients by reducing the symptoms of the disease and extending their survival. Immune checkpoint inhibitors target specific pathways in the immune system, which enables a more targeted approach to cancer treatment. These inhibitors have a lower toxicity profile that leads to fewer side effects and better tolerance to patients as compared to traditional chemotherapy. At present, the rising use of next-generation sequencing technologies that enables the identification of specific genetic mutations in cancer cells is catalyzing the demand for immune checkpoint inhibitors across the globe.

Immune Checkpoint Inhibitors Market Trends:

The surging prevalence of various cancers among individuals, such as melanoma, liver, kidney, and gastric, represents one of the major factors driving the demand for immune checkpoint inhibitors around the world. Moreover, the increasing aging population, which is more prone to develop such severe cancers and the rising prevalence of obesity is favoring the market growth. In addition, there is an increase in the incidences of respiratory disorders on account of the rising consumption of alcoholic beverages and tobacco-based products. This, coupled with the growing numbers of weight-related health concerns on account of unhealthy eating habits and sedentary lifestyles, is influencing the market positively. Apart from this, the surging occurrence of various genetic and lifestyle diseases and the increasing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of cancer is propelling the growth of the market. Furthermore, the expanding number of clinical trials by pharmaceutical companies and the rising preference for personalized medicines and new generation drugs and formulations are propelling the growth of the market. Besides this, the growing focus of leading players on strategic collaborations and new product developments to expand their product portfolio and gain a competitive edge is creating a positive outlook for the market. Additionally, significant improvements in medical infrastructure and diagnostic technologies are anticipated to strengthen the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global immune checkpoint inhibitors market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on type, distribution channel, and application.

Type Insights:

CTLA-4 Inhibitor
PD-1 Inhibitor
PD-L1 Inhibitor


The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the type. This includes CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. According to the report, PD-1 inhibitor represented the largest segment.

Distribution Channel Insights:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies


A detailed breakup and analysis of the immune checkpoint inhibitors market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Application Insights:

Lung Cancer
Bladder Cancer
Melanoma
Colorectal Cancer
Hodgkin Lymphoma
Others


The report has provided a detailed breakup and analysis of the immune checkpoint inhibitors market based on the application. This includes lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. According to the report, lung cancer represented the largest segment.

Regional Insights:

North America

United States
Canada


Asia Pacific

China
Japan
India
South Korea
Australia
Indonesia
Others


Europe

Germany
France
United Kingdom
Italy
Spain
Russia
Others


Latin America

Brazil
Mexico
Others


Middle East and Africa


The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for immune checkpoint inhibitors. Some of the factors driving the North America immune checkpoint inhibitors market included the increasing aging population, presence of a well-established healthcare infrastructure, rising research and development (R&D) activities, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global immune checkpoint inhibitors market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Seagen Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global immune checkpoint inhibitors market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global immune checkpoint inhibitors market?
What is the impact of each driver, restraint, and opportunity on the global immune checkpoint inhibitors market?
What are the key regional markets?
Which countries represent the most attractive immune checkpoint inhibitors market?
What is the breakup of the market based on the type?
Which is the most attractive type in the immune checkpoint inhibitors market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the immune checkpoint inhibitors market?
What is the breakup of the market based on application?
Which is the most attractive application in the immune checkpoint inhibitors market?
What is the competitive structure of the global immune checkpoint inhibitors market?
Who are the key players/companies in the global immune checkpoint inhibitors market?



ページTOPに戻る


Table of Contents

1    Preface
2    Scope and Methodology
    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction
    4.1    Overview
    4.2    Key Industry Trends
5    Global Immune Checkpoint Inhibitors Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Type
    6.1    CTLA-4 Inhibitor
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    PD-1 Inhibitor
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    PD-L1 Inhibitor
        6.3.1 Market Trends
        6.3.2 Market Forecast
7    Market Breakup by Distribution Channel
    7.1    Hospital Pharmacies
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Retail Pharmacies
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Online Pharmacies
        7.3.1 Market Trends
        7.3.2 Market Forecast
8    Market Breakup by Application
    8.1    Lung Cancer
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Bladder Cancer
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Melanoma
        8.3.1 Market Trends
        8.3.2 Market Forecast
    8.4    Colorectal Cancer
        8.4.1 Market Trends
        8.4.2 Market Forecast
    8.5    Hodgkin Lymphoma
        8.5.1 Market Trends
        8.5.2 Market Forecast
    8.6    Others
        8.6.1 Market Trends
        8.6.2 Market Forecast
9    Market Breakup by Region
    9.1    North America
        9.1.1 United States
           9.1.1.1 Market Trends
           9.1.1.2 Market Forecast
        9.1.2 Canada
           9.1.2.1 Market Trends
           9.1.2.2 Market Forecast
    9.2    Asia-Pacific
        9.2.1 China
           9.2.1.1 Market Trends
           9.2.1.2 Market Forecast
        9.2.2 Japan
           9.2.2.1 Market Trends
           9.2.2.2 Market Forecast
        9.2.3 India
           9.2.3.1 Market Trends
           9.2.3.2 Market Forecast
        9.2.4 South Korea
           9.2.4.1 Market Trends
           9.2.4.2 Market Forecast
        9.2.5 Australia
           9.2.5.1 Market Trends
           9.2.5.2 Market Forecast
        9.2.6 Indonesia
           9.2.6.1 Market Trends
           9.2.6.2 Market Forecast
        9.2.7 Others
           9.2.7.1 Market Trends
           9.2.7.2 Market Forecast
    9.3    Europe
        9.3.1 Germany
           9.3.1.1 Market Trends
           9.3.1.2 Market Forecast
        9.3.2 France
           9.3.2.1 Market Trends
           9.3.2.2 Market Forecast
        9.3.3 United Kingdom
           9.3.3.1 Market Trends
           9.3.3.2 Market Forecast
        9.3.4 Italy
           9.3.4.1 Market Trends
           9.3.4.2 Market Forecast
        9.3.5 Spain
           9.3.5.1 Market Trends
           9.3.5.2 Market Forecast
        9.3.6 Russia
           9.3.6.1 Market Trends
           9.3.6.2 Market Forecast
        9.3.7 Others
           9.3.7.1 Market Trends
           9.3.7.2 Market Forecast
    9.4    Latin America
        9.4.1 Brazil
           9.4.1.1 Market Trends
           9.4.1.2 Market Forecast
        9.4.2 Mexico
           9.4.2.1 Market Trends
           9.4.2.2 Market Forecast
        9.4.3 Others
           9.4.3.1 Market Trends
           9.4.3.2 Market Forecast
    9.5    Middle East and Africa
        9.5.1 Market Trends
        9.5.2 Market Breakup by Country
        9.5.3 Market Forecast
10    Drivers, Restraints, and Opportunities
    10.1    Overview
    10.2    Drivers
    10.3    Restraints
    10.4    Opportunities
11    Value Chain Analysis
12    Porters Five Forces Analysis
    12.1    Overview
    12.2    Bargaining Power of Buyers
    12.3    Bargaining Power of Suppliers
    12.4    Degree of Competition
    12.5    Threat of New Entrants
    12.6    Threat of Substitutes
13    Price Analysis
14    Competitive Landscape
    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    AstraZeneca plc
           14.3.1.1 Company Overview
           14.3.1.2 Product Portfolio
           14.3.1.3 Financials
           14.3.1.4 SWOT Analysis
        14.3.2    Bristol-Myers Squibb Company
           14.3.2.1 Company Overview
           14.3.2.2 Product Portfolio
           14.3.2.3 Financials
           14.3.2.4 SWOT Analysis
        14.3.3    GSK plc
           14.3.3.1 Company Overview
           14.3.3.2 Product Portfolio
           14.3.3.3 Financials
           14.3.3.4 SWOT Analysis
        14.3.4    Merck & Co. Inc.
           14.3.4.1 Company Overview
           14.3.4.2 Product Portfolio
           14.3.4.3 Financials
           14.3.4.4 SWOT Analysis
        14.3.5    Ono Pharmaceutical Co. Ltd.
           14.3.5.1 Company Overview
           14.3.5.2 Product Portfolio
           14.3.5.3 Financials
           14.3.5.4 SWOT Analysis
        14.3.6    Pfizer Inc.
           14.3.6.1 Company Overview
           14.3.6.2 Product Portfolio
           14.3.6.3 Financials
           14.3.6.4 SWOT Analysis
        14.3.7    Regeneron Pharmaceuticals Inc.
           14.3.7.1 Company Overview
           14.3.7.2 Product Portfolio
           14.3.7.3 Financials
           14.3.7.4 SWOT Analysis
        14.3.8    Seagen Inc. 
           14.3.8.1 Company Overview
           14.3.8.2 Product Portfolio
           14.3.8.3 Financials
           14.3.8.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

Figure 1: Global: Immune Checkpoint Inhibitors Market: Major Drivers and Challenges
Figure 2: Global: Immune Checkpoint Inhibitors Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Immune Checkpoint Inhibitors Market: Breakup by Type (in %), 2022
Figure 5: Global: Immune Checkpoint Inhibitors Market: Breakup by Distribution Channel (in %), 2022
Figure 6: Global: Immune Checkpoint Inhibitors Market: Breakup by Application (in %), 2022
Figure 7: Global: Immune Checkpoint Inhibitors Market: Breakup by Region (in %), 2022
Figure 8: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Immune Checkpoint Inhibitors (CTLA-4 Inhibitor) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Immune Checkpoint Inhibitors (PD-1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Immune Checkpoint Inhibitors (PD-L1 Inhibitor) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Immune Checkpoint Inhibitors (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Immune Checkpoint Inhibitors (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Immune Checkpoint Inhibitors (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Immune Checkpoint Inhibitors (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Immune Checkpoint Inhibitors (Bladder Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Immune Checkpoint Inhibitors (Melanoma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Immune Checkpoint Inhibitors (Melanoma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: Global: Immune Checkpoint Inhibitors (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Global: Immune Checkpoint Inhibitors (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Global: Immune Checkpoint Inhibitors (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Global: Immune Checkpoint Inhibitors (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: North America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: North America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: United States: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: United States: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: Canada: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: Canada: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: Asia-Pacific: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: Asia-Pacific: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: China: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: China: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: Japan: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: Japan: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: India: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: India: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: South Korea: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: South Korea: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: Australia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: Australia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Indonesia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Indonesia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Europe: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Europe: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Germany: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Germany: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: France: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: France: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: United Kingdom: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: United Kingdom: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: Italy: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: Italy: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Spain: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Spain: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Russia: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Russia: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Latin America: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Latin America: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Brazil: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Brazil: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 74: Mexico: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 75: Mexico: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 76: Others: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 77: Others: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 78: Middle East and Africa: Immune Checkpoint Inhibitors Market: Sales Value (in Million US$), 2017 & 2022
Figure 79: Middle East and Africa: Immune Checkpoint Inhibitors Market: Breakup by Country (in %), 2022
Figure 80: Middle East and Africa: Immune Checkpoint Inhibitors Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 81: Global: Immune Checkpoint Inhibitors Industry: Drivers, Restraints, and Opportunities
Figure 82: Global: Immune Checkpoint Inhibitors Industry: Value Chain Analysis
Figure 83: Global: Immune Checkpoint Inhibitors Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Immune Checkpoint Inhibitors Market: Key Industry Highlights, 2022 & 2028
Table 2: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Type (in Million US$), 2023-2028
Table 3: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 4: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Application (in Million US$), 2023-2028
Table 5: Global: Immune Checkpoint Inhibitors Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Immune Checkpoint Inhibitors Market: Competitive Structure
Table 7: Global: Immune Checkpoint Inhibitors Market: Key Players

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

IMARC Services Private Limited.社の医療分野での最新刊レポート

本レポートと同じKEY WORD(immune)の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


IMARC Services Private Limited.社はどのような調査会社ですか?


インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る